Do we really understand what the immunological disturbances in inflammatory bowel disease mean?

World Journal of Gastroenterology

Volumn 15, Issue 5, 2009, Pages 521-525

  Tsianos, Epameinondas V ^a   Katsanos, Konstantinos ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Immunological disturbances; Inflammatory bowel disease; Pathogenesis; Serological markers

Indexed keywords

AZATHIOPRINE; DEFENSIN; FUNGUS ANTIBODY; INTERLEUKIN 1; INTERLEUKIN 6; METHOTREXATE; OUTER MEMBRANE PROTEIN C; PATTERN RECOGNITION RECEPTOR; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; CYTOKINE PRODUCTION; DEFENSE MECHANISM; EDITORIAL; ENTERITIS; HOST PATHOGEN INTERACTION; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOPATHOLOGY; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; INTESTINE EPITHELIUM; MACROPHAGE; RISK FACTOR; T LYMPHOCYTE;

EID: 63749083117     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.15.521     Document Type: Editorial

References (46)

1. Geboes K. From inflammation to lesion. Acta Gastroenterol Belg 1994; 57: 273-284
2. Kraus TA, Mayer L. Oral tolerance and inflammatory bowel disease. Curr Opin Gastroenterol 2005; 21: 692-696
3. Sartor RB. Current concepts of the etiology and pathogenesis of ulcerative colitis and Crohn's disease. Gastroenterol Clin North Am 1995; 24: 475-507
4. Sartor RB. Pathogenesis and immune mechanisms of chronic inflammatory bowel diseases. Am J Gastroenterol 1997; 92: 5S-11S
5. Shanahan F. Crohn's disease. Lancet 2002; 359: 62-69
6. Holtmann MH, Galle PR. Current concept of pathophysiological understanding and natural course of ulcerative colitis. Langenbecks Arch Surg 2004; 389: 341-349
7. Dignass AU, Baumgart DC, Sturm A. Review article: the aetiopathogenesis of inflammatory bowel disease--immunology and repair mechanisms. Aliment Pharmacol Ther 2004; 20 Suppl 4: 9-17
8. Brandtzaeg P. Inflammatory bowel disease: clinics and pathology. Do inflammatory bowel disease and periodontal disease have similar immunopathogeneses? Acta Odontol Scand 2001; 59: 235-243
9. Gordon JN, Di Sabatino A, Macdonald TT. The pathophysiologic rationale for biological therapies in inflammatory bowel disease. Curr Opin Gastroenterol 2005; 21: 431-437
10. Holtmann MH, Galle PR, Neurath MF. Immunotherapeutic approaches to inflammatory bowel diseases. Expert Opin Biol Ther 2001; 1: 455-466
11. Kolios G, Petoumenos C, Nakos A. Mediators of inflammation: production and implication in inflammatory bowel disease. Hepatogastroenterology 1998; 45: 1601-1609
12. Pallone F, Monteleone G. Regulatory cytokines in inflammatory bowel disease. Aliment Pharmacol Ther 1996; 10 Suppl 2: 75-79; discussion 80
13. Danese S, Gasbarrini A. Chemokines in inflammatory bowel disease. J Clin Pathol 2005; 58: 1025-1027
14. Kobayashi T, Okamoto S, Iwakami Y, Nakazawa A, Hisamatsu T, Chinen H, Kamada N, Imai T, Goto H, Hibi T. Exclusive increase of CX3CR1+CD28-CD4+ T cells in inflammatory bowel disease and their recruitment as intraepithelial lymphocytes. Inflamm Bowel Dis 2007; 13: 837-846
15. Papadakis KA, Prehn J, Zhu D, Landers C, Gaiennie J, Fleshner PR, Targan SR. Expression and regulation of the chemokine receptor CXCR3 on lymphocytes from normal and inflammatory bowel disease mucosa. Inflamm Bowel Dis 2004; 10: 778-788
16. Menzel K, Hausmann M, Obermeier F, Schreiter K, Dunger N, Bataille F, Falk W, Scholmerich J, Herfarth H, Rogler G. Cathepsins B, L and D in inflammatory bowel disease macrophages and potential therapeutic effects of cathepsin inhibition in vivo. Clin Exp Immunol 2006; 146: 169-180
17. Mahida YR. The key role of macrophages in the immunopathogenesis of inflammatory bowel disease. Inflamm Bowel Dis 2000; 6: 21-33
18. Bhavsar MD, Amiji MM. Oral IL-10 gene delivery in a microsphere-based formulation for local transfection and therapeutic efficacy in inflammatory bowel disease. Gene Ther 2008; 15: 1200-1209
19. Li MC, He SH. IL-10 and its related cytokines for treatment of inflammatory bowel disease. World J Gastroenterol 2004; 10: 620-625
20. Neurath MF, Pettersson S, Meyer zum Buschenfelde KH, Strober W. Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice. Nat Med 1996; 2: 998-1004
21. Fedorak RN, Madsen KL. Probiotics and the management of inflammatory bowel disease. Inflamm Bowel Dis 2004; 10: 286-299
22. Jovanovic IR, Milosavjevic TN, Jankovic GP, Micev MM, Dugalic PD, Saranovic D, Ugljesic MM, Popovic DV, Bulajic MM. Clinical onset of the Crohn's disease after eradication therapy of Helicobacter pylori infection. Does Helicobacter pylori infection interact with natural history of inflammatory bowel diseases? Med Sci Monit 2001; 7: 137-141
23. Geboes K, van den Oord J, De Wolf-Peeters C, Desmet V, Rutgeerts P, Janssens J, Vantrappen G, Penninckx F, Kerremans R. The cellular composition of granulomas in mesenteric lymph nodes from patients with Crohn's disease. Virchows Arch A Pathol Anat Histopathol 1986; 409: 679-692
24. Mow WS, Vasiliauskas EA, Lin YC, Fleshner PR, Papadakis KA, Taylor KD, Landers CJ, Abreu-Martin MT, Rotter JI, Yang H, Targan SR. Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. Gastroenterology 2004; 126: 414-424
25. Targan SR, Landers CJ, Yang H, Lodes MJ, Cong Y, Papadakis KA, Vasiliauskas E, Elson CO, Hershberg RM. Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's disease. Gastroenterology 2005; 128: 2020-2028
26. Liew FY, Xu D, Brint EK, O'Neill LA. Negative regulation of toll-like receptor-mediated immune responses. Nat Rev Immunol 2005; 5: 446-458
27. Israeli E, Grotto I, Gilburd B, Balicer RD, Goldin E, Wiik A, Shoenfeld Y. Anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease. Gut 2005; 54: 1232-1236
28. Vermeire S, Peeters M, Vlietinck R, Joossens S, Den Hond E, Bulteel V, Bossuyt X, Geypens B, Rutgeerts P. Anti-Saccharomyces cerevisiae antibodies (ASCA), phenotypes of IBD, and intestinal permeability: a study in IBD families. Inflamm Bowel Dis 2001; 7: 8-15
29. Vermeire S, Joossens S, Peeters M, Monsuur F, Marien G, Bossuyt X, Groenen P, Vlietinck R, Rutgeerts P. Comparative study of ASCA (Anti-Saccharomyces cerevisiae antibody) assays in inflammatory bowel disease. Gastroenterology 2001; 120: 827-833
30. Joossens S, Reinisch W, Vermeire S, Sendid B, Poulain D, Peeters M, Geboes K, Bossuyt X, Vandewalle P, Oberhuber G, Vogelsang H, Rutgeerts P, Colombel JF. The value of serologic markers in indeterminate colitis: a prospective follow-up study. Gastroenterology 2002; 122: 1242-1247
31. Joossens S, Daperno M, Shums Z, Van Steen K, Goeken JA, Trapani C, Norman GL, Godefridis G, Claessens G, Pera A, Pierik M, Vermeire S, Rutgeerts P, Bossuyt X. Interassay and interobserver variability in the detection of anti-neutrophil cytoplasmic antibodies in patients with ulcerative colitis. Clin Chem 2004; 50: 1422-1425
32. Bokoch GM. Regulation of innate immunity by Rho GTPases. Trends Cell Biol 2005; 15: 163-171
33. Elphick DA, Mahida YR. Paneth cells: their role in innate immunity and inflammatory disease. Gut 2005; 54: 1802-1809
34. Watanabe T, Kitani A, Strober W. NOD2 regulation of Toll-like receptor responses and the pathogenesis of Crohn's disease. Gut 2005; 54: 1515-1518
35. Naito Y, Yoshikawa T. Role of matrix metalloproteinases in inflammatory bowel disease. Mol Aspects Med 2005; 26: 379-390
36. Anton PA. Stress and mind-body impact on the course of inflammatory bowel diseases. Semin Gastrointest Dis 1999; 10: 14-19
37. Anton PA, Shanahan F. Neuroimmunomodulation in inflammatory bowel disease. How far from "bench" to "bedside"? Ann N Y Acad Sci 1998; 840: 723-734
38. Webster EL, Torpy DJ, Elenkov IJ, Chrousos GP. Corticotropin-releasing hormone and inflammation. Ann N Y Acad Sci 1998; 840: 21-32
39. Mawdsley JE, Rampton DS. Psychological stress in IBD: new insights into pathogenic and therapeutic implications. Gut 2005; 54: 1481-1491
40. Tsianos EV, Katsanos KH, Christodoulou D, Dimoliatis I, Kogevinas A, Logan RF. Continuing low incidence of Crohn's disease in Northwest Greece. Dig Liver Dis 2003; 35: 99-103
41. Riis L, Vind I, Vermeire S, Wolters F, Katsanos K, Politi P, Freitas J, Mouzas IA, O'Morain C, Ruiz-Ochoa V, Odes S, Binder V, Munkholm P, Moum B, Stockbrugger R, Langholz E. The prevalence of genetic and serologic markers in an unselected European population-based cohort of IBD patients. Inflamm Bowel Dis 2007; 13: 24-32
42. Mitropoulos K. Glossary of the Hippocratic collection. About Epidemics, Ch. VII. Athens, 1989
43. Crohn BB. Granulomatous diseases of the small and large bowel. A historical survey. Gastroenterology 1967; 52: 767-772
44. Tiede I, Fritz G, Strand S, Poppe D, Dvorsky R, Strand D, Lehr HA, Wirtz S, Becker C, Atreya R, Mudter J, Hildner K, Bartsch B, Holtmann M, Blumberg R, Walczak H, Iven H, Galle PR, Ahmadian MR, Neurath MF. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest 2003; 111: 1133-1145
45. Domenech E, Manosa M, Navarro M, Masnou H, Garcia-Planella E, Zabana Y, Cabre E, Gassull MA. Long-term methotrexate for Crohn's disease: safety and efficacy in clinical practice. J Clin Gastroenterol 2008; 42: 395-399
46. Sandborn WJ, Targan SR. Biologic therapy of inflammatory bowel disease. Gastroenterology 2002; 122: 1592-1608